How the 8 Approved Medications Compare ...
Every day seems to bring more exciting news. First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to treat cardiovascular and kidney ...
In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...
This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...
In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...
This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...